Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0002001011-24-000027 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-29 | 2024-02-27 | LGND | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +32.4K | 104.1K | +45% | $0 |
| D | 2024-02-29 | 2024-02-27 | LGND | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +131.7K | 131.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-27 | A | A | 32,436 | $0.00 | 104,145 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2024-02-27 | A | A | 131,723 | $0.00 | 131,723 | D | $89.20 · — to 2034-02-27 | 131,723 Common Stock | (F2) The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. |